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Treatment of hyperphosphatemia in patients with chronic kid-
ney disease on maintenance hemodialysis. Hyperphosphatemia
in patients with ESRD leads to secondary hyperparathyroidism,
renal osteodystrophy, and is independently associated with
mortality risk. The exact mechanism by which hyperphos-
phatemia increases mortality risk is unknown, but it may re-
late to enhanced cardiovascular calcification. National Kidney
Foundation K/DOQI bone metabolism and disease guidelines
recommend maintenance of serum phosphorus (P) below 5.5
mg/dL, and Ca × P product less than 55 mg2/dL2. Although
calcium-based phosphate binders (CBPB) are cost effective,
long-term safety concerns relate to their postulated role in pro-
gression of cardiovascular calcification. Sevelamer hydrochlo-
ride has been recommended as an alternative noncalcium
phosphate binder. Results from the Calcium Acetate Renagel
Evaluation (CARE study) indicate that calcium acetate is more
effective than sevelamer in controlling serum phosphorous
and Ca × P product in hemodialysis patients. In the Treat-to-
Goal study, dialysis patients treated with sevelamer had slower
progression of coronary and aortic calcification than patients
treated with CBPB. The mechanism underlying the beneficial
effect of sevelamer is unknown, but may relate to decreased
calcium loading or to dramatic reductions in LDL cholesterol
in sevelamer-treated patients. At present, evidence incriminat-
ing CBPB in the progression of cardiovascular calcification in
ESRD remains largely circumstantial. As calcium acetate is
more efficacious and cost effective than sevelamer, it remains
an accepted first-line phosphate binder. In this review, we will
examine these issues and provide rational guidelines for the use
of calcium-based phosphate binders in patients on maintenance
hemodialysis.
BACKGROUND
Hyperphosphatemia in patients with chronic kidney
disease (CKD) not only underlies the development of sec-
ondary hyperparathyroidism and renal osteodystrophy,
but is also independently associated with an increased
risk of death among dialysis patients [1, 2]. The mech-
anism by which hyperphosphatemia increases mortality
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risk is not yet clear, but it is thought to promote cardio-
vascular calcification. Vascular calcification, a marker of
atherosclerosis and arterial stiffness, is common among
dialysis patients, and appears to be a very significant risk
factor for cardiovascular mortality. Based on the asso-
ciation of hyperphosphatemia and elevated calcium ×
phosphorus (Ca × P) product with increased cardiovas-
cular mortality in dialysis patients, the National Kidney
Foundation (NKF) Kidney Disease Quality Outcome Ini-
tiative (K/DOQI) Bone Metabolism and Disease guide-
lines call for more rigorous control of serum phospho-
rus, serum calcium, and Ca × P product (Table 1) [3].
In the setting of CKD, secondary hyperparathyroidism
develops as a consequence of phosphate retention, as
well as the reduced renal production of active vitamin
D, resulting in hyperphosphatemia, hypocalcemia, and
increased parathyroid hormone (PTH) levels. Over the
long term, the same factors cause parathyroid gland hy-
perplasia and autonomous PTH production (tertiary hy-
perparathyroidism) [4, 5]. A chronic decrease in serum
calcium and 1,25-dihydroxyvitamin D levels, or an in-
crease in serum phosphorous, leads to a secondary in-
crease in serum PTH as a result of increases in PTH
gene expression, synthesis, and secretion and the eventual
proliferation of parathyroid chief cells with gland hyper-
plasia. Low serum calcium leads to an increase in PTH
secretion, an increase in PTH messenger RNA stability,
and parathyroid cell proliferation. Chronic increases in
serum phosphorous also regulate PTH secretion in a sim-
ilar manner. The effects of calcium on parathyroid cells
are mediated by a membrane-bound calcium-sensing re-
ceptor. These pathophysiologic mechanisms underlying
the development of hyperphosphatemia and secondary
hyperparathyroidism in CKD provide the clinical ratio-
nal for treatment strategies that include maintenance
of normal serum phosphorus levels (dietary phosphorus
restriction, dietary phosphate binders, and short daily
hemodialysis), maintenance of normal serum calcium
(reduced dialysate calcium levels and judicious use of
vitamin D analogues), suppression of PTH secretion
(phosphorus control, maintenance of normocalcemia,
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Table 1. NKF K/DOQI recommended treatment goals
Laboratory parameter Treatment goal
Serum phosphorus 3.5–5.5 mg/dL
Serum calcium 8.4–9.5 mg/dL
Ca × P product <55 mg2/dL2
Intact PTH 150–300 pg/mL
Serum total CO2 >22 mmol/L
Abbreviations: NKF K/DOQI, National Kidney Foundation–Kidney Disease
Outcomes Quality Initiative; Ca × P product, calcium times phosphorus product;
PTH, parathyroid hormone.
and treatment with vitamin D analogues and/or cal-
cimimetic agents such as cinacalcet).
Prevention and treatment of hyperphosphatemia
Large cross-sectional studies have found mean serum
phosphorus of 6.2 mg/dL in the maintenance hemodial-
ysis population in the United States [1]. Moreover, an
alarming 60% of patients had serum phosphorus levels
in excess of the 5.5 mg/dL target level recommended by
K/DOQI guidelines. Patients with end-stage renal dis-
ease develop hyperphosphatemia because their dietary
intake exceeds phosphorous elimination by intermittent
thrice-weekly dialysis. Dietary restriction of phosphorus,
although important, is difficult to accomplish since dialy-
sis patients are encouraged to consume a relatively high
protein diet in order to prevent protein malnutrition [6].
Similarly, intermittent hemodialysis alone does not ade-
quately control serum phosphorus in most patients. How-
ever, the use of more frequent dialysis, such as short
daily hemodialysis or long nocturnal hemodialysis, may
be effective in achieving the recommended goal serum
phosphorus level without the use of phosphate binders.
Unfortunately, these dialysis modalities are still in the
experimental stage, and have not yet been widely ap-
plied in clinical practice. Thus, most patients with stage 5
CKD on maintenance dialysis require dietary phosphate
binders to achieve adequate control of serum phospho-
rus and Ca × P product. The ideal phosphate binder
should bind large amounts of dietary phosphate in the
intestine without producing significant adverse effects. It
should also be relatively inexpensive, since most dialysis
patients require relatively large daily doses of the binder.
Unfortunately, none of the currently used phosphate
binders fulfill all these requirements. This predicament is
best exemplified by aluminum hydroxide, which is prob-
ably the most cost-effective phosphate binder, but has
largely been abandoned for long-term therapy because
of the risks of aluminum intoxication with encephalopa-
thy and osteomalacia. As a result, calcium-based
phosphate binders (CBPB) such as calcium acetate and
calcium carbonate came to replace aluminum hydrox-
ide as the most widely prescribed phosphate binders.
However, recent concern over the possible risks of cal-
cium loading from these binders has led to introduction
of the considerably more expensive noncalcium, non-
aluminum phosphate binder, sevelamer hydrochloride
(Renagel) [7]. At present in clinical practice, calcium
acetate and sevelamer hydrochloride are the two most
commonly prescribed phosphate binders in the United
States. Previous studies comparing these two binders sug-
gested that they are equally effective in controlling serum
phosphorus [7–11]. However, in most of these studies,
sevelamer hydrochloride was not found to be particularly
effective in maintaining serum phosphorus below the rec-
ommended goal of 5.5 mg/dL [8–10]. Given the enor-
mous financial burden of caring for the ever-increasing
dialysis population in the United States, it is impera-
tive that newer and more expensive therapy be shown
to be at least equally efficacious in achieving the desired
treatment goals. The recently published CARE study
was a prospective, randomized, double-blind, multicen-
ter study that compared the efficacy and safety of calcium
acetate and sevelamer hydrochloride for the treatment
of hyperphosphatemia in patients with CKD on main-
tenance hemodialysis [12]. The study design is shown
in Table 2. The primary end points of the study were
to determine whether calcium acetate or sevelamer hy-
drochloride best achieves recently recommended treat-
ment goals for serum phosphorus ≤5.5 mg/dL and Ca ×
P product <55 mg2/dL2. Baseline characteristics of pa-
tients receiving calcium acetate (N = 48) or sevelamer
hydrochloride (N = 50) were similar with respect to age,
gender, race, years on dialysis, and vitamin D therapy. In
addition, patients in both groups had similar baseline val-
ues for serum phosphorus, serum calcium, Ca × P prod-
uct, iPTH, and serum bicarbonate (HCO3). At all time
points in the 8-week study, the serum phosphorus con-
centration (Fig. 1) and the Ca × P product (Fig. 2) were
significantly lower in patients receiving calcium acetate.
Comparisons between the two groups demonstrated that
time-averaged concentrations (weeks 1 to 8) of serum
phosphorus and Ca × P product were significantly lower
in calcium acetate-treated patients (serum phosphorus:
1.08 mg/dL difference, P = 0.0006; Ca × P product: 6.1
mg2/dL2 difference, P = 0.022). At each treatment week,
calcium acetate recipients were 20% to 24% more likely
to attain goal serum phosphorus [odds ratio (OR) 2.37,
95% confidence interval (CI) 1.28–4.37, P = 0.0058], and
15% to 20% more likely to attain goal Ca × P product
(OR 2.16, 95% CI 1.20–3.86, P = 0.0097).
An analysis of 7 previously published randomized tri-
als concluded that calcium-based binders and sevelamer
appear to be similarly efficacious in controlling serum
phosphorus [13]. These studies are in contrast to the
CARE study findings of superior efficacy of calcium ac-
etate. However, it should be noted that the week 8 dose
of sevelamer (6.9 ± 3.6 g/day) in the CARE study was
larger than the sevelamer dosages employed in any of
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Table 2. Study design—Calcium Acetate Renagel Evaluation (CARE study)
Randomized, double-blind, multicenter study
100 adult stage 5 CKD patients on maintenance dialysis at least 3 months
Baseline iPTH <1000 pg/mL without prior parathyroidectomy
1 to 3 week washout period off phosphate binders until serum phosphorus >6 mg/dL
Prestudy dose of vitamin D maintained constant during 8-week treatment phase
Dialysate calcium maintained constant at 2.5 mEq/L (1.25 mmol/L) during study
Randomized to 8 weeks treatment with either:
Calcium acetate (667 mg) Sevelamer hydrochloride (403 mg)
Initial binder dose based on serum phosphorus concentration at end of washout:
Serum P <7.5 mg/dL 2 capsules 3 times per day with meals
Serum P 7.5–9 mg/dL 3 capsules 3 times per day with meals
Serum P >9 mg/dL 4 capsules 3 times per day with meals
Binder dose increased weekly as needed to achieve goal serum P <5.5 mg/dL
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Fig. 1. Mean (± SE) serum phosphorus levels at baseline and weekly
during treatment with either calcium acetate (open circles) or sevelamer
hydrochloride (closed diamonds). At baseline, mean serum phospho-
rus levels were not significantly different between the two groups (P =
0.99). Calcium acetate reduced mean serum phosphorus below the tar-
get level of 5.5 mg/dL by the third week of treatment, and maintained
serum phosphorus below the target level until week 8. In the sevelamer
hydrochloride treatment group, mean serum phosphorus never fell be-
low the target level throughout the 8-week treatment period. Over-
all, serum phosphorus levels were significantly lower during treatment
with calcium acetate than during treatment with sevelamer hydrochlo-
ride (1.08 mg/dL difference in Cavg during weeks 1–8, P value 0.0006
by covariate-adjusted regression). To convert values for phosphorus to
millimoles per liter, multiply by 0.32. Adapted from Qunibi WY et al.
Kidney Int 65:1914–1926, 2004, with permission.
the other seven randomized trials. This discrepancy may
be attributable to differences in study subject populations
or patient selection bias. In this regard, in contrast to the
CARE study, in the Treat-to-Goal study patients were
excluded if their serum phosphorus exceeded 8 mg/dL at
the end of the binder washout phase [11]. Furthermore,
observational cross-sectional studies tend to suggest that
calcium-containing phosphate binders are more effica-
cious than sevelamer [abstracts; Ciampi MA et al, J Am
Soc Nephrol 13:586A, 2002; Block GA, J Am Soc Nephrol
12:761A, 2001]. Analysis of a series of maintenance dial-
ysis patients referred to our institution for kidney trans-
plantation by one of us (Nolan, unpublished observation)
also indicates that sevelamer-treated patients have sig-
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Fig. 2. Mean (± SE) serum calcium × phosphorus product at baseline
and weekly during treatment with either calcium acetate (open circles)
or sevelamer hydrochloride (closed diamonds). At baseline, Ca × P
product was not significantly different between the two groups (P =
0.91). However, Ca×P product was significantly lower during treatment
with calcium acetate than with sevelamer hydrochloride (6.1 mg2/dL2
difference in Cavg during weeks 1–8, P value < 0.0001 by covariate-
adjusted regression). To convert from units of mg2/dL2 to mmol2/L2,
multiply by 0.08. Adapted from Qunibi WY et al. Kidney Int 65:1914–
1926, 2004, with permission.
nificantly higher serum phosphorus and Ca × P products
than calcium acetate-treated patients (Table 3). In this
series, 55% of sevelamer-treated patients had serum P >
5.5 mg/dL, whereas only 27% of calcium-acetate treated
patients exceeded the K/DOQI guideline for serum
phosphorus.
Effect of phosphate binder therapy on serum
calcium levels
In the CARE study, the mean serum calcium level
was significantly higher in the calcium acetate-treated
patients compared to patients treated with sevelamer hy-
drochloride (Fig. 3). Varying among post-baseline weeks
1 to 8, but with no evident time trend, at each week, 2%
to 9% of calcium acetate-treated patients were hypercal-
cemic as defined by serum calcium level ≥11.0 mg/dL. By
contrast, no patient in the sevelamer-treated group devel-
oped hypercalcemia. Regression analysis confirmed that
S-16 Nolan and Qunibi: Hyperphosphatemia treatment in CKD patients on maintenance hemodialysis
Table 3. Observational studies comparing efficacy of sevelamer and calcium-containing phosphate binders in clinical practice
Sevelamer-treated patients Calcium-containing binder patients
Study N P Ca Ca × P Dose N P Ca Ca × P Dosea
Nolan 29 6.2 ± 2.0b 8.4 ± 0.6 52 ± 15b 5.5 ± 3.1 56 5.1 ± 1.5 8.6 ± 0.7 43 ± 14 1125 ± 590
Ciampi [4] 30 6.5 ± 1.2b 9.6 ± 0.7b 62 ± 16b 7.8 ± 3.5 25 5.4 ± 1.5 9.1 ± 0.6 50 ± 15 1359 ± 636
Block [5] 164 5.7 ± 1.4b 9.4 ± 0.9b 54 ± 13b N/R 191 5.2 ± 1.4 9.2 ± 0.7 48 ± 13 N/R
Abbreviations: P, serum phosphorus (mg/dL); Ca, serum calcium (mg/dL); Ca × P, calcium-phosphate product (mg2/dL2); N/R, not reported.
aDose of calcium-containing phosphate binder expressed as mg elemental calcium.
bP < 0.05 compared to calcium-containing binder treated patients.
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Fig. 3. Mean (± SE) serum calcium levels at baseline and weekly dur-
ing treatment with either calcium acetate (open circles) or sevelamer
hydrochloride (closed diamonds). At baseline, mean serum calcium was
not significantly different between the two groups (P = 0.84). Overall,
serum calcium levels were significantly higher during treatment with
calcium acetate than with sevelamer hydrochloride (0.63 mg/dL differ-
ence in Cavg during weeks 1–8, P value < 0.0001 by covariate-adjusted
regression). To convert values for calcium to millimoles per liter, mul-
tiply by 0.25. Adapted from Qunibi WY et al. Kidney Int 65:1914–1926,
2004, with permission.
hypercalcemia was more likely to develop in the calcium
acetate group (summary OR 6.1, 95% CI 2.8–13.3, P <
0.0001). Overall, transient hypercalcemia developed in 8
of 48 (16.7%) calcium acetate-treated patients. Although
there was a positive correlation between calcium acetate
dose and the serum calcium levels, the correlation was
weak, and hypercalcemia tended to develop at relatively
low doses of calcium acetate (Fig. 4A). In this regard, it
should be noted that hypercalcemia occurred only in cal-
cium acetate-treated patients concomitantly treated with
intravenous vitamin D preparations. Hypercalcemia was
not observed in calcium acetate-treated patients not on
vitamin D therapy.
In contrast, hypocalcemia developed more frequently
in sevelamer-treated patients. Varying among post-
baseline weeks 1 to 8, but with no evident time trend,
at each treatment week, 7% to 24% of sevelamer
hydrochloride-treated patients experienced hypocal-
cemia, defined as serum calcium level ≤8.5 mg/dL,
compared to 2% to 13% of calcium acetate-treated pa-
tients. Overall, 50% of sevelamer-treated patients had
at least one episode of hypocalcemia compared to 27%
of the calcium acetate-treated patients. The pathogen-
esis of hypocalcemia in sevelamer-treated patients has
not been carefully studied. There was no correlation
between sevelamer dose and the serum calcium levels
(Fig. 4B). Thus, it is possible that in the sevelamer hy-
drochloride group withdrawal of calcium-based binders
in the washout period was sufficient to cause a net neg-
ative calcium balance and hypocalcemia in patients on
maintenance hemodialysis with dialysate calcium con-
centration fixed at 2.5 mEq/L. The long-term sequelae
of chronic hypocalcemia in sevelamer-treated patients
are currently being debated. Lowrie and Lew reported
that serum calcium level <8.8 mg/dL was associated with
nearly 3-fold increase in the mortality risk [14]. Similarly,
Foley et al found an association between low serum cal-
cium level and the risk of death [15]. To avoid hypocal-
cemia, Chertow et al have recommended that patients
treated with sevelamer receive a night-time supplement
of 900 mg of elemental calcium per day [16].
Role of calcium-containing phosphate binders in
progression of cardiovascular calcification
Vascular calcification is an important issue in dialysis
patients given that it is associated with increased risk of
cardiovascular mortality. However, the underlying causes
of excessive cardiovascular calcification in patients with
advanced CKD are incompletely understood and the sub-
ject of intense study [17]. Cardiovascular calcification is
most likely a multifactorial process with numerous poten-
tial pathogenic factors, including hyperparathyroidism,
phosphate loading with hyperphosphatemia, hyperten-
sion, abnormal glucose metabolism, abnormalities in lipid
metabolism, treatment with vitamin D analogues, and
possibly deficiencies of kidney-derived inhibitors of vas-
cular calcification such as bone morphogenic protein-7
[18]. Thus, it may be overly simplistic to implicate oral
calcium loading from CBPB as the single most important
pathogenic factor in the development of cardiovascular
calcification in dialysis patients.
Data from observational studies suggest that coronary
artery calcium scores and large vessel calcification cor-
relate with the prescribed daily dose of calcium-based
phosphate binders (CBPB) [19, 20]. The Treat-to-Goal
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Fig. 4. Phosphate binder-serum calcium dose-response curves. (A)
Calcium acetate-serum calcium dose-response curve. Individual patient
data from the CARE study with weekly serum calcium levels plotted
against the corresponding calcium acetate dose for that week. Hyper-
calcemic values (>11 mg/dL) are shown as black circles, hypocalcemic
values (<8.5 mg/dL) are shown as gray circles. Calcium values between
8.5 and 11 mg/dL are represented as open circles. There was a statisti-
cally significant correlation between serum calcium level and the dose
of calcium acetate. However, episodes of transient hypercalcemia oc-
curred at relatively low doses of calcium acetate, and were observed in
only 8 out of 48 patients, each of whom was receiving concomitant vita-
min D therapy. (Slope = 0.041, 95% CI 0.027 to 0.055; intercept = 9.11,
95% CI 8.97 to 9.26; R2 = 0.08; adjusted R2 = 0.08; P < 0.001 by linear
regression analysis). CI, 95% confidence interval about the regression
line. (B) Sevelamer hydrochloride-serum calcium dose-response curve.
Individual patient data from the CARE study with weekly serum cal-
cium values plotted against the corresponding sevelamer hydrochlo-
ride dose for that week. Hypocalcemic values (<8.5 mg/dL) are shown
as gray circles. Calcium values between 8.5 and 11 mg/dL are repre-
sented as open circles. There was no statistically significant correlation
between sevelamer dose and serum calcium level. Episodes of hypocal-
cemia were common, and occurred in 50% of sevelamer-treated pa-
tients. Overall, hypocalcemia was present during 17.4% of all treatment
observations in the sevelamer group. Hypercalcemia was not observed
in any patient in the sevelamer treatment group. (Slope = −0.0017,
95% CI −0.0090 to 0.0056; intercept = 9.00, 95% CI 8.89 to 9.11;
R2 = 0.00; adjusted R2 = 0.00; P = 0.64 by linear regression analysis.
study demonstrated that maintenance dialysis patients
treated with sevelamer hydrochloride have slower pro-
gression of coronary and aortic calcification than patients
treated with calcium-containing phosphate binders [11].
In a more recent post hoc analysis of Treat-to-Goal study
results, Chertow et al conclude that oral calcium loading
resulting from treatment with CBPB is the key factor as-
sociated with progressive coronary artery and aortic cal-
cification in dialysis patients [21]. Although the authors
conclude that their findings were most likely due to ex-
cess calcium loading during treatment with CBPB, the
design of the study makes it virtually impossible to test
the validity of this hypothesis. Unfortunately, the study
was not designed such that nonphosphate binder expo-
sure to calcium was kept similar between the calcium-
based binder and sevelamer treatment groups. Instead,
supplemental (nonbinder) sources of calcium were in-
deed provided to the sevelamer-treated patients in at
least three forms: (1) the study design allowed for the use
of calcium carbonate supplements at night on an empty
stomach to treat hypocalcemia in the sevelamer treat-
ment group; (2) the dialysate calcium concentration was
adjusted during the study in order to maintain normal
serum calcium levels; (3) sevelamer-treated patients re-
ceived larger doses of vitamin D analogues, which might
be expected to enhance gastrointestinal absorption of di-
etary calcium. Chertow et al previously recommended
giving 900 mg elemental calcium at bedtime on empty
stomach to sevelamer-treated patients in order to pre-
vent hypocalcemia and adequately suppress PTH [16].
Balance studies in normal individuals indicate that when
calcium acetate is given with a meal, 26% of the avail-
able elemental calcium is absorbed, whereas 30% of ad-
ministered elemental calcium is absorbed when calcium
carbonate is given with a meal [22]. In contrast, when
calcium carbonate is given on an empty stomach, 39%
of the administered calcium is absorbed from the gas-
trointestinal tract [23]. Based on theoretical analysis of
gastrointestinal calcium absorption in the various treat-
ment groups in the Treat-to-Goal study (Table 4), it is
apparent that patients in the sevelamer treatment group
receiving calcium carbonate supplementation at night
were actually exposed to a greater dietary calcium load
than study subjects treated with calcium acetate as a phos-
phate binder. Furthermore, higher average vitamin D
doses in the sevelamer group suggest that the possibil-
ity that they could have experienced further increases
in absorption of calcium available from the diet and the
night-time calcium carbonate supplement. Table 4 further
illustrates that the subgroup of CBPB-treated patients
receiving calcium carbonate were theoretically exposed
to greater gastrointestinal calcium loading than patients
treated with calcium acetate. Nonetheless, another post
hoc analysis of the Treat-to-Goal study demonstrated that
there was no difference in the rates of progression of
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Table 4. Predicted gastrointestinal calcium absorption in various treatment groups in the Treat-to-Goal study [11]
Calcium acetate Calcium carbonate Sevelamer plus calcium
Binder group in Treat-to-Goal Study phosphate binder phosphate binder carbonate supplement
Total binder/supplement dose mg/day 4600 mga 3900 mga 2250 mga
Elemental calcium dose % contentb 25% 40% 40%
mg/day 1150 mg 1560 mg 900 mg
Predicted GI calcium absorption % absorption 26%c 30%c 39%d
mg/day 299 mg 468 mg 351 mg
GI, gastrointestinal.
aCalcium-based binder and supplement doses at week 52 of study.
bPercentage of elemental calcium contained in each compound.
cPercentage of calcium absorbed from the GI tract in normal subjects given calcium-containing phosphate binder with a meal [22].
dPercentage of calcium absorbed from GI tract when calcium carbonate given to normal individuals on an empty stomach [23].
coronary and aortic calcification when comparing pa-
tients treated with calcium acetate to those treated
with calcium carbonate [24]. Another confounding vari-
able with regard to the Treat-to-Goal study design is
the failure to maintain the dialysate calcium concentra-
tions constant in the two treatment groups. Although
the actual dialysate calcium concentrations used in the
two treatment groups have never been reported, the
most recent post hoc analysis indicates that the fi-
nal dialysate calcium concentrations were indeed dif-
ferent in the sevelamer and CBPB treatment groups
[21]. Balance studies indicate that patients treated
with dialysate containing 2.5 mEq/L (1.25 mmol/L)
calcium are in neutral calcium balance during dialy-
sis [25]. Higher dialysate calcium leads to net trans-
fer of calcium to the patient, while lower dialysate
calcium leads to negative calcium balance. Thus, if
dialysate calcium concentrations were indeed higher in
sevelamer-treated patients, this would provide yet an-
other potential source of nonbinder calcium supplemen-
tation. In sum, these observations suggest that some
factor other than simply oral calcium loading from the
use of CBPB is responsible for the finding that sevelamer-
treated patients have slower progression of cardiovas-
cular calcification. Moreover, given these deficiencies in
study design, it is virtually impossible for the Treat-to-
Goal study investigators to conclude from any type of
post hoc analysis that their finding of a slower rate of
progression in the sevelamer treatment group was due to
“reduced calcium loading.”
The failure to achieve equivalent control of LDL and
total cholesterol is another critical issue with regard to
interpretation of the Treat-to-Goal study results. Since
sevelamer is a bile acid sequestrant, in comparison to
CBPB-treated patients, sevelamer-treated patients had
significantly lower levels of total cholesterol (182 ± 49 vs.
141 ± 28 mg/dL; P < 0.0001) and LDL cholesterol (103 ±
43 vs. 65 ± 21 mg/dL; P < 0.0001) [11]. Since LDL lev-
els have been shown to play an important role in pro-
gression of coronary artery calcification in the general
population, the Treat-to-Goal investigators should have
controlled the LDL level in the two treatment groups to
similar levels. In this regard, lowering LDL cholesterol
with HMG-CoA reductase inhibitor therapy has been re-
ported to ameliorate or even reverse coronary artery cal-
cification in at least two studies [26, 27], one of which was
coauthored by Dr. Raggi, a senior author of the Treat-
to-Goal study [26]. Preliminary results of a recent study
from Japan demonstrate that progression of aortic calcifi-
cation in dialysis patients was significantly retarded dur-
ing treatment with colestimide (a bile acid sequestrant
similar to sevelamer) in combination with atorvastatin
compared with the progression rate during the observa-
tion period before lipid-lowering therapy was instituted
[28]. The authors speculate that the decrease in aortic cal-
cification resulted from control of serum phosphorus and
LDL cholesterol levels. Thus, available information sug-
gests that the dramatic reduction of LDL cholesterol is
a very compelling potential explanation for the reduced
rate of cardiovascular calcification in sevelamer-treated
dialysis patients.
The critically important issue of increased cardiovas-
cular calcification and mortality in dialysis patients can
only be addressed by well-designed studies that control
for not only the type of phosphate binder, but also for
the myriad potential risk factor associated with vascular
calcification. Until such studies are available, it is clearly
premature to abandon calcium-based phosphate binders
in favor of sevelamer because the latter is clearly less
efficacious for control of serum phosphorus and calcium-
phosphate product and considerably more expensive.
Comparative costs of phosphate binder therapy
The cost of medications remains an important issue in
dialysis patients. Based on CARE study week 8 doses
and average wholesale prices for PhosLo and Renagel
[29], the projected annual per patient cost for treatment
with calcium acetate would be $732 compared to $4,283
for sevelamer. Thus, if sevelamer were to be universally
adopted as the first-line phosphate binder, the cost for
treatment of the roughly 300,000 dialysis patients in the
United States would increase by over 1.0 billion dollars
annually. Although the lipid-lowering effect of sevelamer
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may have a beneficial role in slowing the progression of
cardiovascular calcification in dialysis patients [11], cost-
benefit analysis reveals that combined treatment with an
HMG-CoA reductase inhibitors and calcium-containing
phosphate binders would be a far more cost-effective al-
ternative. Given the enormous financial burden of caring
for the steadily increasing dialysis population, it is im-
perative that expensive phosphate binders such as seve-
lamer meet the following criteria prior to adoption as a
preferred therapeutic option: (1) similar efficacy to cal-
cium acetate in achieving K/DOQI guidelines for serum
phosphorus and Ca × P product; (2) validation of bene-
ficial effects of sevelamer on rates of hospitalization and
mortality in dialysis patients. In our opinion, sevelamer
has not yet been shown to meet either of these criteria.
Based on their pharmacoeconomics analysis, Mann et al
conclude that the hypothesized benefits of sevelamer on
cardiovascular mortality must be tested in well-designed
randomized intervention trials prior to embarking on na-
tional program to expand Medicare coverage to cover
the cost of sevelamer [13]. CARE study data and cross-
sectional studies suggest that in clinical practice the actual
dosages of sevelamer required to achieve adequate phos-
phorus control are likely to be considerably higher than
those employed in previously published studies. Thus, the
true financial burden of widespread implementation of
the K/DOQI Bone Metabolism guidelines for phosphate
binder therapy may well be substantially greater than
the costs projected in the recent pharmacoeconomics
analysis.
Effects of phopshate binders on acid-base balance in
dialysis patients
Numerous short- and long-term studies indicate that
treatment with sevelamer hydrochloride causes a signifi-
cant reduction in serum bicarbonate levels compared to
patients treated with calcium-based phosphate binders.
Sevelamer hydrochloride is a quaternary amine anion
exchange resin that binds monovalent phosphate in ex-
change for release of the leaving anion chloride. This
anion exchange resin may also exchange chloride for
any other anion present in the lumen of the gastroin-
testinal tract. In the small intestine, the local concen-
tration of HCO3 is in the range of 120 mEq/L, owing
the alkaline secretions from the pancreas. Thus, con-
centration gradients in the small intestine would favor
exchange of chloride for bicarbonate with loss of carbon-
ated sevelamer in the stool. The ongoing GI loss of bi-
carbonate in excess of chloride would lead to acid load-
ing and metabolic acidosis through a mechanism akin
to chronic diarrhea. Sevelamer can also exchange chlo-
ride for bile acid, and thereby function to lower serum
cholesterol by acting as a bile acid sequestrant similar to
cholestyramine. Each of these three mechanisms could
theoretically lead to generation of a net dietary acid load
during treatment with sevelamer hydrochloride. Since
sevelamer hydrochloride contains 17% chloride, com-
plete exchange of chloride for phosphate, bicarbonate,
or bile acid would lead to a potential net acid load of ap-
proximately 4 mEq for each 800 mg sevelamer tablet.
Dietary acid loading during treatment with sevelamer
hydrochloride has been confirmed in an animal model
[abstract; Nolan et al, J Am Soc Nephrol 14:15A, 2003].
Normal rats fed a diet containing sevelamer hydrochlo-
ride develop a significant decrease in urine pH, and a sig-
nificant increase in urinary ammonium excretion, as mea-
sured by ion-specific electrode. Acidemia should clearly
be avoided in patients with chronic renal failure because
it has two major systemic consequences. Metabolic aci-
dosis has several effects on bone, causing physiochemi-
cal dissolution of bone and cell-mediated bone resorp-
tion by inhibition of osteoblast function and stimulation
of osteoclast function [30–32]. Chronic metabolic acido-
sis also induces a net negative nitrogen and total body
protein balance, which improve after bicarbonate sup-
plementation [33, 34]. These data suggest that metabolic
acidosis is both catabolic and anti-anabolic. These con-
siderations underscore the urgent need for further stud-
ies of acid-base balance during long-term treatment with
sevelamer hydrochloride. Given the detrimental effects
of metabolic acidosis on nitrogen balance and bone, the
K/DOQI guidelines recommend maintaining serum total
CO2 greater than 22 mmol/L [3, 6].
CONCLUSION
The CARE study demonstrates that patients with
CKD on maintenance hemodialysis are more effectively
treated with calcium acetate compared with sevelamer
hydrochloride, and more frequently achieve the K/DOQI
treatment goals for serum phosphorus, Ca × P prod-
uct, and bicarbonate. Cost-benefit analysis clearly favors
calcium acetate as the first-line therapy of choice for
treatment of hyperphosphatemia in dialysis patients. The
hypothesized benefits of sevelamer on cardiovascular
mortality must be tested in well-designed randomized
intervention trials prior to embarking on national pro-
gram to expand Medicare coverage to cover the cost of
sevelamer.
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